Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1997 Aug;88(8):760–769. doi: 10.1111/j.1349-7006.1997.tb00448.x

Antitumor Effect of DX‐8951, a Novel Camptothecin Analog, on Human Pancreatic Tumor Cells and Their CPT‐11‐resistant Variants Cultured in vitro and Xenografted into Nude Mice

Soichi Takiguchi 1, Eiji Kumazawa 2, Takao Shimazoe 1, Akiko Tohgo 2, Akira Kono 1,✉
PMCID: PMC5921502  PMID: 9330608

Abstract

DX‐8951 is a novel water‐soluble derivative of camptothecin. We evaluated the effects of DX‐8951 on the growth of several pancreatic tumor cell lines in vitro and in vivo. In vitro cytotoxic activity of DX‐8951 against SUIT‐2 and KP‐1N cells, as indicated by IC50 value, was several times more potent than that of SN‐38, an active metabolite of CPT‐11, and dozens of times more potent than that of SK&F104864 (topotecan). DX‐8951 also showed the greatest cytotoxicity against CPT‐11‐resis‐tant variants, SUIT‐2/CPT‐11 and KP‐1N/CPT‐11 cells, and the cross‐resistance of these cells to DX‐8951 was lower than that to SN‐38 and SK&F104864. Topoisomerase 1 inhibitory activity of DX‐8951 was about three‐fold stronger than that of SN‐38, as measured in crude nuclear extract obtained from SUIT‐2 cells. DX‐8951 induced DNA fragmentation, a specific feature of apoptosis, in SUIT‐2 cells more effectively than SN‐38. DX‐8951 exhibited potent antitumor effects against SUIT‐2 in a solid tumor model and in a liver metastasis model, in which tumor cells were xenografted sub‐cutaneously and intrasplenically, respectively, into nude mice. The in vivo effects were closely similar to or somewhat superior to those of CPT‐11, DX‐8951 also showed significant antitumor effects against SUIT‐2/CPT‐11 solid tumors, against which CPT‐11 had no effect. These results suggest that, on the basis of its strong antitumor activity and effectiveness against CPT‐11‐resistant tumors, DX‐8951 may be a useful therapeutic agent in the treatment of human cancer. The potent cytotoxicity of DX‐8951 may result from strong inhibition of topoisomerase I, which may then trigger apoptotic cell death.

Keywords: DX‐8951f, Camptothecin, Pancreatic cancer, Drug resistance, Nude mice

Full Text

The Full Text of this article is available as a PDF (599.8 KB).

REFERENCES

  • 1. ) Wall , M. E , Wani , M. C , Cook , C. E , Palmar , K. H , McPhail , A. T. and Sim , G. A.Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata . J. Am. Chem. Soc. , 88 , 3888 – 3890 ( 1966. ). [Google Scholar]
  • 2. ) Gallo , R. C. , Whang‐Peng , J. and Adamson , R. H.Studies on the antitumor activity, mechanisms of action, and cell cycle effects of camptothecin . J. Natl. Cancer Inst. , 46 , 789 – 795 ( 1971. ). [PubMed] [Google Scholar]
  • 3. ) Muggia , F. M. , Creaven , P. J. , Hansen , H. H. , Cohen , M. H. and Selawry , O. S.Phase I clinical trial of weekly and daily treatment with camptothecin (NSC‐100880), correlation with preclinical studies . Cancer Chemother. Rep. , 56 , 515 – 521 ( 1972. ). [PubMed] [Google Scholar]
  • 4. ) Kunimoto , T. , Nitta , K. , Tanaka , T. , Uehara , N. , Baba , H. , Takeuchi , M. , Yokokura , T. , Sawada , S. , Miyasaka , T. and Mutai , M.Antitumor activity of 7‐ethy1‐10‐[4‐(1‐piperidino) ‐1 ‐piperidino] carbonyloxycamptothecin, a novel water‐soluble derivative of camptothecin, against murine tumors . Cancer Res. , 47 , 5944 – 5947 ( 1987. ). [PubMed] [Google Scholar]
  • 5. ) Kawato , Y. , Furuta , T. , Aonuma , M. , Yasuoka , M. , Yokokura , T. and Matsumoto , K.Antitumor activity of a camptothecin derivative, CPT‐11, against human tumor xenografts in nude mice . Cancer Chemother, Pharmacol , 28 , 192 – 198 ( 1981. ). [DOI] [PubMed] [Google Scholar]
  • 6. ) Takeda , S. and Kono , A.Inhibitory effects of CPT‐11 on liver metastases in nude mice injected with human pancreatic tumor cells into their spleens . Jpn. J. Cancer Chemother. , 17 , 2433 – 2436 ( 1990. ), in Japanese . [PubMed] [Google Scholar]
  • 7. ) Ohno , R. , Okada , K. , Masaoka , T. , Kuramoto , A. , Arima , T. , Yoshida , Y. , Ariyoshi , H. , Ichimaru , M. , Sakai , Y. , Oguro , M. , Ito , Y. , Morishima , Y. , Yokomaku , S. and Ota , K.An early phase II study of CPT‐11, a new derivative of camptothecin, for the treatment of leukemia and lymphoma . J. Clin. Oncol , 8 , 1907 – 1912 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 8. ) Masuda , N. , Fukuoka , M. , Kusunoki , Y. , Matsui , K. , Takifuji , N. , Kudoh , S. , Negoro , S. , Nishioka , M. , Nakagawa , K. and Takada , M.CPT‐11, a new derivative of camptothecin for the treatment of refractory or relapsed small‐cell lung cancer . J. Clin. Oncol , 10 , 1225 – 1229 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 9. ) Fukuoka , M. , Niitani , H. , Suzuki , A. , Motomiya , M. , Hasegawa , K. , Nishiwaki , Y. , Kuriyama , T. , Ariyoshi , Y. , Negoro , S. , Masuda , N. , Nakajima , S. and Taguchi , T.A phase II study of CPT‐11, a new derivative of camptothecin, for previously untreated non‐small‐cell lung cancer . J. Clin. Oncol. , 10 , 16 – 20 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 10. ) Shimada , Y. , Yoshino , M , Wakui , A , Nakao , I. , Futatsuki , K. , Sakata , Y. , Kambe , M. , Taguchi , T. and Ogawa , N.Phase II study of CPT‐11, a new camptothecin derivative, in metastatic colorectal cancer . J. Clin. Oncol , 11 , 909 – 913 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 11. ) Futatsuki , K. , Wakui , A. , Nakao , I. , Sakata , Y. , Kambe , M. , Shimada , Y. , Yoshino , M. , Taguchi , T. and Ogawa , N.Late phase II study of Irinotecan hydrochloride (CPT‐11) in advanced gastric cancer . Jpn. J. Cancer Chemother. , 21 , 1033 – 1038 ( 1994. ), in Japanese . [PubMed] [Google Scholar]
  • 12. ) Takeuchi , S. , Takamizawa , H. , Takeda , Y. , Okawa , T. , Tamaya , T. , Noda , K. , Sugawa , T. , Sekiba , K. , Yakushiji , M. and Taguchi , T.Clinical study of CPT‐11, camptothecin derivative, on gynecological malignancy . Proc. Am. Soc. Clin. Oncol , 10 , 189 ( 1991. ). [Google Scholar]
  • 13. ) Kawato , Y. , Aonuma , M. , Hirota , Y. , Kuga , H. and Sato , K.Intracellular role of SN‐38, a metabolite of camptothecin derivative CPT‐11, in the antitumor effect of CPT‐11 . Cancer Res. , 51 , 4187 – 4190 ( 1991. ). [PubMed] [Google Scholar]
  • 14. ) Hsiang , Y. R. , Hertzberg , S. , Hecht , S. and Leu , L. F.Camptothecin induces protein‐linked DNA breaks via mammalian DNA topoisomerase I . J. Biol. Chem. , 260 , 14873 – 14878 ( 1985. ). [PubMed] [Google Scholar]
  • 15. ) Kaufmann , S. H.Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin and other cytotoxic anticancer drugs, a cautionary note . Cancer Res. , 49 , 5870 – 5878 ( 1989. ). [PubMed] [Google Scholar]
  • 16. ) Tanizawa , A. , Fujimori , A. , Fujimori , Y. and Pommier , Y.Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials . J. Natl. Cancer Inst. , 86 , 836 – 842 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 17. ) Huang , R. W. , Takatsuki , K. and Tsuda , H.A new derivative of camptothecin, irinotecan hydrochloride (CPT‐11) induces programmed cell death in leukemia/ lymphoma cell lines . Int. J. Oncol , 3 , 679 – 685 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 18. ) Kondo , S. , Yin , D. , Morimura , T. and Takeuchi , J.bcl‐2 gene prevents induction of apoptosis in L1210 murine leukemia cells by SN‐38, a metabolite of the camptothecin derivative CPT‐11 . Int. J. Oncol , 4 , 649 – 654 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 19. ) Terasawa , H. , Ohsuki , S. and Uoto , K.Hexa‐cyclic compound. European Patent 0495432A1 ( 1992. ).
  • 20. ) Mitsui , I. , Kumazawa , E. , Hirota , Y. , Aonuma , M. , Sugimori , M. , Ohsuki , S. , Uoto , K. , Ejima , A. , Terasawa , H. and Sato , K.A new water‐soluble camptothecin derivative, DX‐8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo . Jpn. J. Cancer Res. , 86 , 776 – 782 ( 1995. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. ) Wagener , D. J. T. , Verdonk , H. E. R. , Dirix , L. Y. , Catimel , G. , Siegenthaler , P. , Buitenhuis , M. , Mathier‐Boue , A. and Verweij , J.Phase II trial of CPT‐11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study . Ann. Oncol , 6 , 129 – 132 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 22. ) Sakata , Y. , Shimada , Y. , Yoshino , M. , Kambe , M. , Futatsuki , K. , Nakao , L , Ogawa , N. , Wakui , A. , and Taguchi , T.A late phase II study of CPT‐11, irinotecan hydrochloride, in patients with advanced pancreatic cancer . Jpn. J. Cancer Chemother. , 21 , 1039 – 1046 ( 1994. ), in Japanese . [PubMed] [Google Scholar]
  • 23. ) Iwamura , T. , Katsuki , T. and Ide , K.Establishment and characterization of a human pancreatic cancer cell line (SUIT‐2) producing carcinoembryonic antigen and carbohydrate antigen 19–9 . Jpn. J. Cancer Res. (Gann ), 78 , 54 – 62 ( 1987. ). [PubMed] [Google Scholar]
  • 24. ) Ikeda , Y. , Ezaki , M. , Hayashi , I. , Yasuda , D. , Nakayama , K. and Kono , A.Establishment and characterization of human pancreatic cancer cell lines in tissue culture and in nude mice . Jpn. J. Cancer Res. , 81 , 987 – 993 ( 1990. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. ) Takeda , S. , Shimazoe , T. , Sato , K. , Sugimoto , Y. , Tsuruo , T. and Kono , A.Differential expression of DNA topoisomerase I gene between CPT‐11 acquired‐ and native‐resistant human pancreatic tumor cell lines, detected by RNA/PCR‐based quantitation assay , Biochem. Biophys. Res. Comtnun. , 184 , 618 – 625 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 26. ) Kozlowski , J. M. , Fidler , I. J. , Campbell , D. , Xu , Z. , Edward Kaighn , M. and Hart , L R.Metastatic behavior of human tumor cell lines grown in the nude mouse . Cancer Res. , 44 , 3522 – 3529 ( 1984. ). [PubMed] [Google Scholar]
  • 27. ) Kingsbury , W. D. , Boehm , J. C. , Jakas , D. R. , Holden , K. G. , Hecht , S. M. , Gallagher , G. , Caranfa , M. J. , McCabe , F. L. , Faucette , L. F. , Johnson , R. K. and Hertzberg , R. P.Synthesis of water‐soluble (aminoalkyl) camptothecin analogues, inhibition of topoisomerase I and antitumor activity./ . Med. Chem. , 34 , 98 – 107 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 28. ) Mosmann , T.Rapid colorimetric assay for cellular growth and survival, application to proliferation and cytotoxicity assays . J. Immunol Methods , 65 , 55 – 63 ( 1983. ). [DOI] [PubMed] [Google Scholar]
  • 29. ) Boliver , F. , Rodriguez , R. L. , Greene , P. J. , Betlach , M. C. , Heynecker , H. L. , Boyer , H. W. , Crosa , J. H. and Falkow , S.Construction and characterization of new cloning vehicles . Gene , 2 , 95 – 113 ( 1977. ). [PubMed] [Google Scholar]
  • 30. ) Liu , L. F. and Miller , K. G.Eukaryotic DNA topoisomerases, two forms of type I DNA topoisomerases from HeLa cell nuclei . Proc. Natl. Acad. Sci. USA , 78 , 3487 – 3491 ( 1981. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. ) Smith , C. A. , Williams , G. T. , Kingston , R. , Jenkinson , E. J. and Owen , J. T.Antibodies to CD3/T‐cell receptor complex induce death by apoptosis in immature T cells in thymic cultures . Nature , 337 , 181 – 184 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 32. ) Fujita , F. , Fujita , M. , Taguchi , T. , Shimozuma , K. , Sakamoto , Y. , Kimoto , Y. and Hirai , T.Multifactorial analysis of parameters influencing chemosensitivity of human cancer xenografts in nude mice . Int. J. Cancer , 43 , 637 – 644 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 33. ) Sugimoto , Y. , Tsukahara , S. , Oh‐hara , T. , Isoe , T. and Tsuruo , T.Decreased expression of DNA topoisomerase I in caraptothecin resistant tumor cell lines as determined by a monoclonal antibody . Cancer Res. , 50 , 6925 – 6930 ( 1990. ). [PubMed] [Google Scholar]
  • 34. ) Kanzawa , F. , Sugimoto , Y. , Minato , K. , Kasahara , K. , Bungo , M. , Nagakawa , K. , Fujisawa , Y. , Liu , L. F. and Saijo , N.Establishment of a camptothecin analogue (CPT‐11)‐resistant cell line of human non‐small cell lung cancer, characterization and mechanism of resistance . Cancer Res. 50 , 5919 – 5924 ( 1990. ). [PubMed] [Google Scholar]
  • 35. ) Nagai , S. , Yamauchi , M. , Andoh , T. , Nishizawa , M. , Satta , T. , Kodera , Y. , Kondou , K. , Akiyama , S. , Ito , K. and Takagi , H.Establishment and characterization of human gastric and colonic xenograft lines resistant to CPT‐11 (a new derivative of camptothecin) J. Surg. Oncol. , 59 , 116 – 124 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 36. ) Kubota , N. , Ohta , S. , Takeda , Y. , Ohmori , T. , Nishio , K. , Morikage , T. , Fujiwara , Y. , Kanzawa , F. and Saijo , N.Detection of topoisomerase I gene mutation in CPT‐11 resistant lung cancer cell line . Biochem. Biophys. Res. Commun. , 188 , 571 – 577 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 37. ) Aogi , K. , Nishiyama , M. , Hirabayashi , N. , Toge , T. , Okada , K. , Kusano , T. and Ando , T.Establishment of a new multidrug‐resistant cell line induced by continuous exposure to CPT‐11 . Proc. Am. Assoc. Cancer Res. , 35 , 451 ( 1994. ). [Google Scholar]
  • 38. ) Ogasawara , H. , Nishio , K. , Kanzawa , F. , Lee , Y.‐S. , Funayama , Y. , Ohira , T. , Kuraishi , Y. , Isogai , Y. and Saijo , N.Intracellular carboxyl esterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW‐2189 in cell lines resistant to cisplatin and CPT‐11 . Jpn. J. Cancer Res. , 86 , 124 – 129 ( 1995. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. ) Mitsui , I. , Ohsuki , S. , Hirota , Y. , Sugimori , M. , Terasawa , H. and Sato , K.High potency of a camptothecin derivative DX‐8951 might be attributed to good membrane permeability . Proc. Am. Assoc. Cancer Res. , 35 , 455 ( 1994. ). [Google Scholar]
  • 40. ) Tanizawa , A. , Kohn , K. W. , Kohlhagen , G. , Leteurtre , F. and Pommier , Y.Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives . Biochemistry , 34 , 7200 – 7206 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 41. ) Ohmori , T. , Podack , E. R. , Nishio , K. , Takahashi , M. , Miyahara , Y. , Takeda , Y. , Kubota , N. , Funayama , Y. , Ogasawara , H. , Ohira , T. , Ohta , S. and Saijo , N.Apoptosis of lung cancer cells caused by some anti‐cancer agents (MMC, CPT‐11, ADM) is inhibited by bcl‐2 . Biochem. Biophys. Res. Commun. , 192 , 30 – 36 ( 1993. ). [DOI] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES